Abstract
Introduction
Over the last decade, the introduction of drug--eluting stents (DES) has greatly changed the world of interventional cardiology [1] . First-generation DES with releasing antiproliferative agents from permanent polymer coatings have shown better performance in reducing the risk of restenosis and subsequent revascularization than bare metal stents [2] , but at the expense of an increased occurrence of very late stent thrombosis (ST) [3, 4] . Incomplete endothelialization, delayed vessel healing and remodeling due to chronic inflammation within stented segment are likely to cause concerns for the DES [5, 6] . The persistence of durable polymer coatings on DES might trigger the inflammation reaction after completed drugs elution [5, 7, 8] . To address the problem, different stent coating strategies have been developed [9] including biocompatible durable polymers, biodegradable polymers DES (BP-DES) and polymer-free DES. Second-generation DES are coated with a thinner permanent and biocompatible fluorocopolymer [1, 9] . Many trials have been conducted to indicate the lower rate of ST in patients treated with second-generation DES during long--term follow-up [10] . Nevertheless, the ongoing minimal inflammation process related to durable polymer materials is still under observation [11, 12] .
Biodegradable polymer coatings on DES are regarded as a promising step forward in polymer technology [13] . BP-DES could provide a non--thrombogenic coating of exposed stent surfaces to decrease the risk of late complications [13] [14] [15] [16] [17] [18] . Prior reports [15, 17] have revealed that biodegradation of the polymers within 6-9 months had promising long-term clinical results, especially regarding very late ST. In the latest SORT OUT V trial [19] , however, it was found that the incidence of ST was 0.7% for biodegradable polymers based biolimus-eluting stents (Nobori) and 0.2% for permanent polymers sirolimus-eluting Cypher stents at both 9 and 12 months (p = 0.034). Because of the low rates of ST [1] , individual trials comparing BP-DES and permanent polymers-DES (PP-DES) were not appropriately powered to detect a statistically significant difference in the rates of adverse events [20] . We conducted a meta-analysis, which increases the statistical reliability by summarizing the results from all available trials, to investigate the short-and long-term effects and the ST rate of BP-DES compared with PP-DES in patients undergoing percutaneous coronary intervention (PCI).
Methods

Selection criteria
Eligibility criteria were: (1) randomized clinical trials (RCTs) comparing BP-DES with PP-DES in patients undergoing PCI; (2) studies reporting data on the outcomes of interest (reported below). Exclusion criteria were: (1) duplicated data; (2) sub-study of the RCT; (3) ongoing trials.
Search strategy
Studies were identified by searching electronic databases including Medline, Embase, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL). This search was supplemented by scanning reference lists of eligible studies and relevant websites (www. clinicaltrialresults.org, www.tctmd.com, www.theheart.org, www.cardiosource.com, www.escardio. org). No limits were applied for language, date, or publication status. The following keywords and corresponding Medical Subject Headings were used: "bioresorbable", "bioabsorbable", "biodegradable", "drug-eluting stent", and "drug-coated stent". The last search was run on 8 June 2013.
Study selection and data collection
Two independent investigators (XWN, CLY) assessed reports for eligibility at title and/or abstract level, and then extracted data from shortlisted studies on pre-specified forms. Information included: (1) the trial's design, inclusion and exclusion criteria; (2) baseline patient and lesion characteristics; (3) features of the intervention and control arms; (4) clinical outcomes. In an attempt to overcome incomplete or selective data reporting, manuscripts that were presented at a meeting but had not yet been published in full-text form were included. As to missing or unclear information, we tried to contact original trial researchers by telephone or e-mail.
Assessment of risk of bias in individual studies
Two investigators independently (XWN, CLY) evaluated the internal validity of eligible trials in accordance with a set of 7 criteria of the Cochrane Handbook [21] : random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias (adequate description of sample size calculation and detailed disclosures of sources of funding). The judgements of bias were expressed as "Low risk", "High risk" or "Unclear risk". All divergences were resolved by consensus.
Study outcomes and definitions
The primary endpoints chosen for this meta--analysis were the cumulative rates of definite/probable ST as well as the occurrences of early/late (0 days to 1 year), very late (> 1 year) definite/probable ST. The secondary endpoints were ischemia-driven target lesion revascularization (TLR), myocardial infarction (MI), all-cause death. Endpoints occurred within 1 year follow-up time were defined as the short-term outcomes and those beyond 1 year as the long-term. Studies reporting only target vascular revascularization but not TLR data were excluded in TLR analyses.
The definitions of definite/probable ST and MI complied with the Academic Research Consortium (ARC) criteria [22] . TLR was defined as any percutaneous or surgical revascularization of the target lesion owing to symptoms or objective signs of ischemia as well as luminal renarrowing ≥ 50% detected by angiography at follow-up.
Statistical analysis
Two investigators (DC, YLY) examined data from all identified studies. When 2 or more RCTs were available for data pooling, meta-analyses were conducted for any outcome according to the intention-to-treat principle. Because of rare events and imbalance between groups, dichotomous outcomes were analyzed by computing pooled odds ratios (ORs) with 95% confidence intervals (CIs) using the DerSimonian and Laird random-effects model [21] . Effect of treatment could not be assessed in trials when no events were reported in two arms. For trials in which no event occurred in one group, an automatic 'zero cell' correction was used in such groups [23] . Statistical heterogeneity was evaluated by the Cochrane Q test and the I 2 statistic (with p values < 0.1 and I 2 values > 50% regarded as significant inconsistency) [21] . We used the funnel plot and Egger's tests to evaluate the presence of publication bias for the endpoints [21] . Sensitivity analyses were conducted to assess the consistency of primary outcomes, including different stent types and dual antiplatelet therapy duration (aspirin and thienopyridine). The treatment effects were examined by testing whether consecutively deleting each trial would change the overall treatment effect of the meta-analysis dramatically. All endpoints were evaluated in separate subgroup analyses according to the pre-specified stratified lengths of follow-up time. Results were statistically significant at two-sided p < 0.05. Statistical computations were performed with Review Manager 5.1 (the Cochrane Collaboration, Copenhagen, Denmark) and Stata 11.0 (College Station, Texas, USA).
Results
Eligible studies
From a total number of 836 potentially relevant publications, 19 RCTs with 27 studies met the inclusion criteria and were selected. Seventeen of these were full-text articles [19, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] and 2 were meeting presentation [40, 41] . A flow diagram depicting the process of search strategy is shown in Figure 1 , and main characteristics of the included studies are described in Table 1 . Among a total number of 20,229 patients that were enrolled, 11,134 were randomized to receive BP-DES, and 9,095 to PP-DES. Biodegradable polymer sirolimus-eluting stents (SES) was used in 9 trials (3,716 patients) and biolimus-eluting stents with a biodegradable polymer in 8 trials (6,034 patients). The remaining 2 trials used respectively everolimus and paclitaxel as drugs coated on BP-DES. With regard to the PP--DES arm, all the patients from the included studies were treated either with first-generation DES, SES (4,481 patients) and paclitaxel-eluting stents (1,003 patients), or with second-generation DES, everolimus-eluting stents (EES) (3,611 patients). The mean age of participants in individual trials ranged from 57 to 69 years with the majority of patients being male. The percentage of diabetes mellitus ranged from 15% to 60%. Patients with acute MI were included in 8 trials [19, 25-27, 30, 32, 33, 38] . Recommended duration of dual antiplatelet therapy was at least 6 months in all trials except for 3 [38, 40, 41] . Follow-up ranged from 9 to 48 months and a weighted mean follow-up was 25.8 months. Some additional long-term follow-up information was retrieved from web-posted conference proceedings [42] [43] [44] . In terms of ST, only one trial did not adopt the ARC definition [35] . Table 2 lists the risk of bias among studies which were judged by 7 criteria [21] . All but 5 trials were described as randomization and allocation concealment adequate. Clinical endpoints were adjudicated in a blinded manner in 13 trials. All trials had a withdrawal of < 10% at the time of publication of the outcomes of interest in our analysis. Two meeting presentations [40, 41] are registered with ClinicalTrials.gov, number (NCT00825773, NCT00887211), which were not reported in the table.
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Stent thrombosis. 18 RCTs including 18,529 patients reported the frequency of ARC definite or probable ST and were used for the quantitative analysis. Among the studied population, the incidence of overall ST was 0.78% (79 of 10,132) in the BP--DES and 1.10% (92 of 8,397) in the PP-DES during the longest available follow-up period. In terms of the pooled risk of ST, no significant difference could be detected between BP-DES and PP-DES (0.80; 0.58-1.10; p for effect = 0.17; I 2 = 4%; p for heterogeneity = 0.41). A pre-specified stratified analysis for early/late and very late ST was evaluated. The rate of early/late ST was not different between two groups (0.73% vs. 0.82%; 0.92; 0.65-1.31; p for effect = 0.66; I 2 = 1%; p for heterogeneity = 0.43; Fig. 2 ). However, regarding the risk of very late ST, BP-DES use was associated with a nearly 70% reduction when compared with PP-DES (0.3% vs. 0.9%; 0.33; 0.16-0.70; p for effect = 0.003; I 2 = 0%; p for heterogeneity = 0.87; Fig. 2) .
Target lesion revascularization. 17 RCTs including 17,890 patients contributed to the analysis of overall TLR. No significant difference regarding TLR was found with BP-DES vs. PP-DES in short-term follow-up (3.24% vs. 3.80%; 0.93; 0.73-1.19; p for effect = 0.57; I 2 = 31%; p for heterogeneity = 0.12; Fig. 3 ). However, in long--term follow-up, BP-DES use was associated with a significant reduction in the risk of TLR compared with PP-DES (8.42% vs. 10.74%; 0.70; 0.52-0.95; p for effect = 0.02; I 2 = 38%; p for heterogeneity = 0.12; Fig. 3 ). 
Sensitivity and influence analysis
Stratified analyses were performed to evaluate the consistency of our findings (Table 3A, B) . The short-term effect of treatment (BP-DES) on each endpoint was maintained by using £ 6-or 12-month duration of dual antiplatelet therapy, different DES types. The beneficial long-term treatment effect of BP-DES, however, was supported by using first-generation DES as the comparators and 12-month clopidogrel use. The analyses for the BP-DES subtypes (biolimus, sirolimus, paclitaxel or everolimus) found: (1) a significantly lower risk of long-term TLR was associated with the use of all types of BP-DES but paclitaxel-eluting stents compared with PP-DES; (2) biolimus-eluting stents reduced the risk of very late ST in comparison with PP-DES.
Because we included 2 RCTs [40, 41] only with meeting presentations in the present analysis, we repeated all analyses using full-length articles alone. The treatment effects for each outcome were consistent with our overall findings. Additionally, influence analysis demonstrated that no single study obviously changed the pooled ORs for ST, TLR, MI, or death.
Publication bias
Visual inspection of the funnel plot for ST did not reveal an apparent asymmetry ( 
Discussion
Overall findings
In this meta-analysis with 20,229 patients enrolled in 19 randomized trials, main findings could be summarized as follows: (1) BP-DES were associated with decreased risks of definite or probable very late ST and long-term TLR compared with PP-DES, however, the long-term superiority of BP--DES was only maintained by using first-generation DES as the comparators in stratified analyses. (2) BP-DES had similar rates of definite or probable ST and TLR to PP-DES during the short follow--up period. (3) No significant difference was found regarding efficacy and safety between BP-DES and current standard second-generation DES using biocompatible permanent polymer. (4) Both groups had the comparable rates of MI and all-cause death in the short-and long-term follow-up.
Possible mechanisms of benefit
Although differences in DES system performances may be attributed to any of its 3 components, namely a metallic stent platform, an antiproliferative agent, and a coating polymer [1] , some changes in coating strategies may account *Significant comparisons; The pooled estimates are reported as odds ratio (95% confidence interval); BP -biodegradable polymer; PP -permanent polymer; BES -biolimus-eluting stents; DES -drug-eluting stents; EES -everolimus-eluting stent; PES -paclitaxel--eluting stents; SES -sirolimus-eluting stents; DAPT -dual antiplatelet therapy; NA -not applicable cumulative 1-year ST, and very late ST compared with other DES (paclitaxel-, sirolimus-, and zotarolimus-eluting stents). Based on these excellent outcomes, it will be difficult to see any significant differences between BP-DES and EES. In a registry [48] including 814 patients with a median follow-up of 22 months, biolimus-eluting stents were similar to EES regarding safety (ST, MI or death) or efficacy (target vessel revascularization). In future clinical trials, more second-generation DES should be considered competitive comparators to corroborate the present finding.
Additionally, when the clinical follow-up period was extended (> 1 year), the improvement in clinical restenosis (TLR) was maintained in patients treated with BP-DES. This finding was potentially associated with the reduction of the inflammation burden and late catch-up restenosis after implantation of BP-DES [15] . Taken together, both minimization of the risk of very late ST and the long-term potent anti-restenosis effects in part reflected the accelerated re-endothelialization and improved coronary artery healing with BP-DES use.
DES comparisons
Although the results of our stratified analysis showed a consistent short-term effect of treatment among different BP-DES types, we did detect differences in the rates of very late ST and long-term TLR. The potential clinical benefit of BP-DES was thought to fully grow only during the late phase after stent intervention, when the polymer coatings already degraded and antiproliferative dugs completely eluted leaving the stent surface more close to bare-metal scaffolds. Therefore, the influence of the polymers and active drugs composing DES on long-term clinical outcomes seemed negligible, while bare-metal scaffolds may be dominant factors of long-term effects [13, 15, 33, 50] . In fact, meaningful differences regarding ST in head-to-head trials of bare-metal stents have not been reported [50] . In theory, the property of BP-DES might allow shorter duration of dual antiplatelet therapy. However, the beneficial long-term treatment effect of BP-DES was only maintained by using 12-month duration of dual antiplatelet therapy regimens. This might be due to the fact that the complete degradation of most used polymers needed nearly a year [15] . The selection of short-term dual antiplatelet therapy would need to be reconsidered in patients treated with BP-DES. Finally, the estimates variation was due in part to the subdivision of data into several smaller subgroups [51] . for these results. Based on lots of animal experiments and studies in DES-treated human subjects, researchers have demonstrated that very late ST may be caused by incomplete re-endothelialization, delayed arterial healing and remodeling due to the ongoing stented vessel wall inflammation [5, 6] . The etiology of the chronic inflammatory response is multifactorial such as lesion characteristics and patient-, device-, and procedural-related factors, however, the persistence of permanent polymer coatings which eluted antiproliferative drugs was likely a primary inflammatory stimulus [5, 7, 8] . Development of biodegradable polymers on DES meant that the stent would be polymer-free and drug-free like a bare-metal stent after polymer absorption, thereby eliminating the long-term sequelae of durable polymer residue [13, 15, 16] . An optical coherence tomography study [18] showed earlier endothelialization associated with BP-DES vs. PP-DES within 9 months after implantation, indicating an improved vascular chronic inflammation. Hamilos et al. [14] also found better preserved endothelium-dependent vasomotion of BP-DES than that of permanent polymer-coated SES.
Besides biodegradable polymers on DES, the biocompatible fluoropolymers used in the second--generation DES were associated with less thrombogenicity [10] . Although BP-DES offered a theoretical advantage over DES with durable biocompatible polymers [11, 12, 32, 48] , our study failed to demonstrate this benefit. This finding implied that the variability in BP-DES efficacy and safety across control DES reflected a real attenuation of treatment effects. Two recent large meta-analyses [10, 49] have clearly demonstrated that second-generation SES reduced the relative risk of early ST, late ST,
Implications of the present study
Firstly, very late ST, which is a rare event but more prevalent in higher-risk patients and lesions, turned into catastrophic outcomes after 1-year of stents' implantation [22] . In this setting, our meta--analysis had the clinical importance, which revealed a performance difference for very late definite or probable ST between BP-DES and PP-DES use. Secondly, BP-DES have combined the low restenosis rate with the enhanced long-term safety profile. It also supported the earlier evidence that the presence of residual durable polymers in DES initiated a persisting inflammatory reaction, which not only promoted thrombogenity of the device but also potentially increased neointimal hyperplasia within the stented segment [5, 7, 8] . Moreover, the benefit of BP-DES was at least non-inferior to EES, which were regarded as a gold standard to which new stent designs should be compared [32] . The finding provided a justification for trials further evaluating safety of the biodegradable polymer stent design in the long-term follow-up.
Limitations of the study
We cannot deny that our study has several limitations. Firstly, as this meta-analysis is not based on patient-level data, it shares the possible shortcomings of the original articles. Moreover, we could not conduct subset analyses of patients with diabetics, complex lesions, or MI. Secondly, we are unable to extend our findings to other second--generation DES (zotarolimus-eluting stents). Thirdly, the long-term superiority of BP-DES is only against first-generation DES, which are not used in daily clinical practice. Finally, the selection criteria for DES with different coating strategies should have a comprehensive assessment of the overall devices performance rather than taking into consideration only thrombosis susceptibility. Notwithstanding these limitations, studies using the uniform and standardized definition of ST were included in the meta-analysis to decrease the risk of bias. As only RCTs were included, our point estimates for all outcomes were less likely influenced by confounding bias.
Conclusions
The present meta-analysis showed that BP--DES were more efficacious than PP-DES at reducing the risks of very late definite/probable ST and long-term TLR, but it could vary by heterogeneities in the use of PP-DES comparators. No significant differences regarding safety and efficacy outcomes within short follow-up period were observed. RCTs with longer follow-up are warranted to verify these very promising long-term endpoints.
